{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T03:02:22Z","timestamp":1790564542121,"version":"4.1.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T00:00:00Z","timestamp":1658275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T00:00:00Z","timestamp":1658275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Polyganics b.v."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cerebrospinal fluid (CSF) leakage is a frequent and challenging complication in neurosurgery, especially in the posterior fossa, with a prevalence of 8%. It is associated with substantial morbidity and increased healthcare costs. A novel dural sealant patch (LIQOSEAL) was developed for watertight dural closure. The objective of this study is to clinically assess the safety and effectiveness of LIQOSEAL as a means of reducing intra- as well as postoperative CSF leakage in patients undergoing elective posterior fossa intradural surgery with a dural closure procedure compared to the best currently available dural sealants.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We will conduct a two-arm, randomized controlled, multicenter study with a 90-day follow-up. A total of 228 patients will be enrolled in 19 sites, of which 114 will receive LIQOSEAL and 114 an FDA-approved PEG sealant. The composite primary endpoint is defined as intraoperative CSF leakage at PEEP 20 cm H<jats:sub>2<\/jats:sub>O, percutaneous CSF leakage within 90 days of, wound infection within 90 days of or pseudomeningocele of more than 20cc on MRI or requiring intervention. We hypothesize that the primary endpoint will not be reached by more than 10 patients (9%) in the investigational arm, which will demonstrate non-inferiority of LIQOSEAL compared to control.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This trial will evaluate whether LIQOSEAL is non-inferior to control as a means of reducing CSF leakage and safety<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov  <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04086550\">NCT04086550<\/jats:ext-link>. Registered on 11 September 2019<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-022-06490-8","type":"journal-article","created":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T10:02:49Z","timestamp":1658311369000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluate the safety and efficacy of dura sealant patch in reducing cerebrospinal fluid leakage following elective cranial surgery (ENCASE II): study protocol for a randomized, two-arm, multicenter trial"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2189-3699","authenticated-orcid":false,"given":"Andrew P.","family":"Carlson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma M. H.","family":"Slot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan P. C.","family":"van Doormaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the ENCASE II study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. H. J.","family":"Voormolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. W.","family":"Dankbaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Depauw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Brouwers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. R.","family":"Germans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Baert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Vandersteene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. F.","family":"Freyschlag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Freyschlag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Thom\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Zenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Penner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Abdulazim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Beez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Zuccarello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Sauvageau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Welch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Langer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Dehdashti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"VanGompel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Bendok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Chaichana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Dogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. K.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. G.","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,20]]},"reference":[{"key":"6490_CR1","doi-asserted-by":"publisher","unstructured":"Kinaci A, Algra A, Heuts S, O\u2019Donnell D, van der Zwan A, van Doormaal T. Effectiveness of dural sealants in prevention of cerebrospinal fluid leakage after craniotomy: a systematic review. World Neurosurg. 2018. https:\/\/doi.org\/10.1016\/j.wneu.2018.06.196.","DOI":"10.1016\/j.wneu.2018.06.196"},{"issue":"3","key":"6490_CR2","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3171\/2014.6.JNS131917","volume":"121","author":"G Hutter","year":"2014","unstructured":"Hutter G, Von Felten S, Sailer MH, Schulz M, Mariani L. Risk factors for postoperative CSF leakage after elective craniotomy and the efficacy of fleece-bound tissue sealing against dural suturing alone: a randomized controlled trial - Clinical article. J Neurosurg. 2014;121(3):735\u201344.","journal-title":"J Neurosurg"},{"issue":"6","key":"6490_CR3","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.surneu.2005.03.041","volume":"64","author":"JA Grotenhuis","year":"2005","unstructured":"Grotenhuis JA. Costs of postoperative cerebrospinal fluid leakage: 1-year, retrospective analysis of 412 consecutive nontrauma cases. Surg Neurol. 2005;64(6):490\u20133.","journal-title":"Surg Neurol"},{"issue":"8","key":"6490_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s10856-021-06552-4","volume":"32","author":"A Kinaci","year":"2021","unstructured":"Kinaci A, van Thoor S, Redegeld S, van DT TM. Ex vivo evaluation of a multilayered sealant patch for watertight dural closure: cranial and spinal models. J Mater Sci Mater Med. 2021;32(8):85.","journal-title":"J Mater Sci Mater Med"},{"key":"6490_CR5","doi-asserted-by":"publisher","unstructured":"Van Doormaal T, Germans MR, Sie M, Brouwers B, Carlson A, Dankbaar JW, et al. Single-arm, open-label, multicentre first in human study to evaluate the safety and performance of dural sealant patch in reducing CSF leakage following elective cranial surgery: the ENCASE trial. BMJ Open. 2021. https:\/\/doi.org\/10.1136\/bmjopen-2021-049098.","DOI":"10.1136\/bmjopen-2021-049098"},{"issue":"2","key":"6490_CR6","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1093\/ons\/opw004","volume":"13","author":"JM Tew","year":"2017","unstructured":"Tew JM, Strong MJ, Alexanderwest G, Woo H, Couture DE, Wilson JA, et al. A pivotal randomized clinical trial evaluating the safety and effectiveness of a novel hydrogel dural sealant as an adjunct to dural repair. Oper Neurosurg. 2017;13(2):204\u201312.","journal-title":"Oper Neurosurg"},{"issue":"1","key":"6490_CR7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3171\/jns.2007.106.1.52","volume":"106","author":"GR Cosgrove","year":"2007","unstructured":"Cosgrove GR, Delashaw JB, Grotenhuis JA, Tew JM, Van Loveren H, Spetzler RF, et al. Safety and efficacy of a novel polyethylene glycol hydrogel sealant for watertight dural repair. J Neurosurg. 2007;106(1):52\u20138.","journal-title":"J Neurosurg"},{"key":"6490_CR8","unstructured":"Centers for Disease Control and Prevention (CDC). Surgical Site Infection Event (SSI). National Healthcare Safety Network (NHSN). 2021. https:\/\/www.cdc.gov\/nhsn\/psc\/ssi\/index.html Accessed 31 May\u00a02021."},{"key":"6490_CR9","unstructured":"World Medical Association. Declaration of Helsinki. https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki-ethical-principles-for-medical-researchinvolving-human-subjects\/. Accessed 31 May\u00a02021."},{"key":"6490_CR10","unstructured":"International Organization for Standardization. ISO 14155:2011: clinical investigation of medical devices for human subjects \u2013 good clinical practice. International Organization for Standardization. https:\/\/www.iso.org\/standard\/45557.html. Accessed 31 May\u00a02021."},{"key":"6490_CR11","unstructured":"European Union. MEDDEV 2.7\/3 REV 3: clinical investigations: serious adverse reporting under directives 90\/385\/EEC and 93\/42\/EC. European Union. http:\/\/ec.europa.eu\/growth\/sectors\/medical-devices\/current-directives\/guidance_en. Accessed 31 May\u00a02021."},{"key":"6490_CR12","unstructured":"European Union. MEDDEV 2.7\/4: guidelines on clinical investigation:a guide for manufacturers and notified bodies. European Union.http:\/\/ec.europa.eu\/growth\/sectors\/medical-devices\/current-directives\/guidance_en. Accessed 31 May\u00a02021."},{"key":"6490_CR13","unstructured":"Food and Drug Administration. CFR - Code of Federal Regulations Title 21. Food and Drug Administration.https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRsearch.cfm?CFRPart=812. Accessed 31 May\u00a02021."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06490-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06490-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06490-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T10:05:34Z","timestamp":1658311534000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06490-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,20]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["6490"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06490-8","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,20]]},"assertion":[{"value":"7 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is performed in accordance with the World Medical Association Declaration of Helsinki []; ISO 14155:202011 []; the Medical Device Directive (MDD 93\/42\/EEC and MEDDEV 2.7\/3 rev. 3:2015) [] and MEDDEV 2.7\/413 []; FDA regulations for IDE studies (G200118\/S002) including 21 CFR 50, 54, 56, and 81214; and the Health Insurance Portability and Accountability Act []. The protocol was approved by the local ethics committees or institutional review boards of all centers that are currently recruiting: Ethics Committee of Citta\u2019 Della Salute e Della Scienza di Torino #153\/2021, University Hospital Zurich #BASEC 2021-00407, Ghent University Hospital #B6702021000353, University Medical Center Utrecht #NL71524.041.19, Institutional Review Board of University of New Mexico #21-173, University of Texas Southwestern #STU-2019-1127, University of Cincinnati #2021-0336, and Oregon Health and Science University #STUDY00023102.Written, informed consent to participate will be obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"TPCvD received a consultancy fee in the design phase of the product from Polyganics BV.EMHS receives a research grant through Polygancis BV.APC received no financial support from Polyganics BV.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"581"}}